6-Methyl-5-MeO-DMT, or 6-Me-5-MeO-DMT, also known as 5,6-MeOM-DMT, 5-MeO-6,N,N-TMT, or 6-methyl-5-methoxy-N,N-dimethyltryptamine, is a serotonin receptor modulator of the tryptamine and 5-methoxytryptamine families related to the psychedelic drug 5-MeO-DMT. "One desoxy analogue warrants mention. This is known as 5-methoxy-6-methyl-DMT (5,6-MeOM-DMT) or as 5-methoxy-6,N,N-trimethyltryptamine (5-MeO-6,N,N-TMT), where the 6-methoxy group is, in effect, replaced with a 6-methyl group. Having a DMT skeleton, it was assayed parenterally, and even at 15 milligrams (smoking) there was nothing noted. This is a level that would have been dramatic had there been no substitution at that 6-position. Some of the historical background of an oxygen at this position is discussed in the 6-HO-DMT recipe." It is the 6-methyl derivative of 5-MeO-DMT.
According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), 6-Me-5-MeO-DMT is inactive in humans at doses of up to 15mg via smoking. For comparison, 5-MeO-DMT was active at doses of 6 to 20mg smoked.
Unlike 5-MeO-DMT and 7-Me-5-MeO-DMT, 6-Me-5-MeO-DMT is inactive as a serotonin receptor agonist in the rat fundus strip assay and does not substitute for 5-MeO-DMT in rodent drug discrimination tests. However, 6-Me-5-MeO-DMT has subsequently been found to be a potent and high-efficacy agonist of the serotonin 5-HT2A and 5-HT2C receptors but not of the serotonin 5-HT2B receptor.
The chemical synthesis of 6-Me-5-MeO-DMT has been described.
6-Me-5-MeO-DMT was first described in the scientific literature by Richard Glennon and colleagues by 1980. Subsequently, it was further described by Shulgin in TiHKAL in 1997.
See also Substituted tryptamine 6-Methyl-DMT 6-Methyltryptamine 7-Me-5-MeO-DMT 5,6-MeO-MiPT 5,6-MDO-DMT
References
External links 6-Methyl-5-MeO-DMT - Isomer Design